Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neos Therapeutics Inc. NEOS

Healthcare Drug Manufacturers - Major
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In... see more

Recent & Breaking News (NDAQ:NEOS)

Neos Therapeutics Appoints Jerry McLaughlin as Chief Executive Officer

GlobeNewswire June 27, 2018

Neos Therapeutics to Participate in Two June Conferences

GlobeNewswire May 31, 2018

Neos Therapeutics to Present at the UBS Global Healthcare Conference

GlobeNewswire May 15, 2018

Neos Therapeutics Reports First Quarter 2018 Financial Results

GlobeNewswire May 9, 2018

Neos Therapeutics to Host First Quarter 2018 Financial Results Conference Call on May 9, 2018

GlobeNewswire May 2, 2018

Neos Therapeutics Announces US Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old

GlobeNewswire October 2, 2017

Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Eagle Pharma, Neos Therapeutics, and Zynerba Pharma

PR Newswire September 22, 2017

Mid-Afternoon Market Update: Silver Spring Networks Climbs On Acquisition News; Finish Line Shares Plunge

Benzinga.com  September 18, 2017

12 Biggest Mid-Day Losers For Monday

Benzinga.com  September 18, 2017

Mid-Day Market Update: Dow Gains 75 Points; Nabriva Therapeutics Shares Spike Higher

Benzinga.com  September 18, 2017

Mid-Morning Market Update: Markets Open Higher; Northrop Grumman To Acquire Orbital ATK

Benzinga.com  September 18, 2017

A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street

Benzinga.com  September 18, 2017

Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older

GlobeNewswire September 15, 2017

Neos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old

GlobeNewswire September 5, 2017

Neos Therapeutics to Participate in Three September Conferences

GlobeNewswire August 30, 2017

Generic Drugs Stock Performance Review -- Pacira Pharma, Eagle Pharma, Neos Therapeutics, and Zynerba Pharma

PR Newswire August 11, 2017

Neos Therapeutics Reports Second Quarter 2017 Financial Results

GlobeNewswire August 8, 2017

Investor Network: Neos Therapeutics, Inc. to Host Earnings Call

Accesswire August 8, 2017

Neos Therapeutics to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017

GlobeNewswire August 2, 2017

Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days

Benzinga.com  July 5, 2017